-
Mashup Score: 6
An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The Food and Drug Administration (FDA) approved capmatinib and tepotinib on May 6, 2020, and February 3, 2021, respectively. Capmatinib is indicated for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 1 …
Source: PubMedCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 7Capmatinib-Induced Pseudo–Acute Kidney Injury: A Case Report - 3 year(s) ago
We present a case of pseudo acute kidney injury (AKI) following capmatinib therapy in an 84-year-old male with combined non-small cell (adenocarcinoma) and small cell lung cancer with MET Exon 14 skipping mutation. His past medical history was significant for chronic kidney disease (CKD) stage 3 with a baseline serum creatinine (SCr) of 1.6 mg/dl rising to 2.44 mg/dL [estimated glomerular…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Pardon Our Interruption - 4 year(s) ago
As you were browsing www.clinicaloncology.com something about your browser made us think you were a bot. There are a few reasons this might happen: You’re a power user moving through this website with super-human speed. You’ve disabled JavaScript in your web browser. A third-party browser plugin, such…
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA approves Tabrecta for certain patients with metastatic NSCLC - 4 year(s) ago
The FDA granted accelerated approval to capmatinib for treatment of certain patients with metastatic non-small cell lung cancer.The approval applies to use of capmatinib (Tabrecta, Novartis) — an oral kinase inhibitor that targets MET — for adults whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. The agent can be used as first-line
Source: bit.lyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
BREAKING: Regular #FDA approval has been granted to #capmatinib for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test. #nsclc #lcsm https://t.co/1E9JPGW3s6